publication venue for
- COVID-19 Breakthrough Infections in Immune-Mediated Inflammatory Diseases: Data from the SUCCEED (Safety and Immunogenicity of COVID-19 Vaccines in Systemic Autoimmune-Mediated Inflammatory Diseases) Study.. 13:104. 2025
- Methotrexate and Tumor Necrosis Factor Inhibitors Independently Decrease Neutralizing Antibodies after SARS-CoV-2 Vaccination: Updated Results from the SUCCEED Study.. 12:1061. 2024
- How Safe Are COVID-19 Vaccines in Individuals with Immune-Mediated Inflammatory Diseases? The SUCCEED Study.. 12:1027. 2024
- Strategic Planning of a Joint SARS-CoV-2 and Influenza Vaccination Campaign in the UK. 12:158-158. 2024
- Model-Based Planning and Delivery of Mass Vaccination Campaigns against Infectious Disease: Application to the COVID-19 Pandemic in the UK. 9:1460-1460. 2021
- Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers. 9:1125-1125. 2021
- Modeling the Impact of COVID-19 Vaccination in Lebanon: A Call to Speed-Up Vaccine Roll Out. 9:697-697. 2021
- Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI. 9:685-685. 2021
- Neutrophils and Influenza: A Thin Line between Helpful and Harmful. 9:597-597. 2021
- The Impact of Rubella Vaccine Introduction on Rubella Infection and Congenital Rubella Syndrome: A Systematic Review of Mathematical Modelling Studies. 9:84-84. 2021
- Antibody and Cell-Mediated Immune Responses Are Correlates of Protection against Influenza Infection in Vaccinated Older Adults. 9:25-25. 2021
- In-Depth Analysis of Genetic Variation Associated with Severe West Nile Viral Disease. 8:744-744. 2020
- Comparative Immunogenicity of the 2014–2015 Northern Hemisphere Trivalent IIV and LAIV against Influenza A Viruses in Children. 7:87-87. 2019
- Relative Clinical and Cost Burden of Community-Acquired Pneumonia Hospitalizations in Older Adults in the United States—A Cross-Sectional Analysis. 6:59-59. 2018
- “Gnothi Seauton”: Leveraging the Host Response to Improve Influenza Virus Vaccine Efficacy. 6:23-23. 2018